Relation of myeloperoxidase promoter polymorphism and long-term hormone replacement therapy to oxidized low-density lipoprotein autoantibodies in postmenopausal women

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 5, 2006, Pages 371-384

  Mäkelä, Riikka ^a,b   Dastidar, P ^a,b   Jokela, H ^a   Jaakkola, O ^a,b,c   Saarela, M ^a,b   Punnonen, R ^a,b   Lehtimaki T ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Atherosclerosis; Hormone replacement therapy; LDL oxidation; Myeloperoxidase

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; DNA; ESTRADIOL VALERATE; GESTAGEN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN DEFICIENCY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; APOLIPOPROTEINS; ATHEROSCLEROSIS; AUTOANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; LIPOPROTEINS, LDL; MIDDLE AGED; PEROXIDASE; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 33747104835     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600727603     Document Type: Article

References (60)

1. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
2. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-75.
3. Punnonen RH, Jokela HA, Dastidar PS, Nevala M, Laippala PJ. Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women. Maturitas 1995;21:179-87.
4. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981;1:858-60.
5. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
7. Jokela H, Dastidar P, Rontu R, Salomaki A, Teisala K, Lehtimaki T, et al. Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab 2003;88:4348-54.
8. Lehtimaki T, Dastidar P, Jokela H, Koivula T, Lehtinen S, Ehnholm C, et al. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to functional apolipoprotein e genotype. J Clin Endocrinol Metab 2002;87:4147-53.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
10. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:23-7.
11. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
12. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605-9.
13. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980;93:480-9.
14. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-44.
15. Heinecke JW. Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders. J Lab Clin Med 1999;133:321-5.
16. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97:1535-44.
17. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-81.
18. Pentikainen MO, Oorni K, Kovanen PT. Myeloperoxidase and hypochlorite, but not copper ions, oxidize heparin-bound LDL particles and release them from heparin. Arterioscler Thromb Vasc Biol 2001;21:1902-8.
19. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
20. Zhang C, Reiters C, Eiserich JP, Boersma B, Parks DA, Beckman JS, et al. L-arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 2001;276:27159-65.
21. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604.
22. Jansson G. Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes: a possible cause of oxidative stress in inflammatory cells. Free Radic Res Commun 1991;14:195-208.
23. Santanam N, Shern-Brewer R, McClatchey R, Castellano PZ, Murphy AA, Voelkel S, et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998;39:2111-8.
24. Bekesi G, Kakucs R, Varbiro S, Feher J, Pazmany T, Magyar Z, et al. Induced myeloperoxidase activity and related superoxide inhibition during hormone replacement therapy. BJOG 2001;108:474-81.
25. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
26. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-7.
27. Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9.
28. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003:S172-6.
29. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999;155:31-41.
30. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997;78:97-107.
31. Reynolds WF, Stegeman CA, Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002;103:154-60.
32. Koivu TA, Dastidar P, Jokela H, Nikkari ST, Jaakkola O, Koivula T, et al. The relation of oxidized LDL autoantibodies and long-term hormone replacement therapy to ultrasonographically assessed atherosclerotic plaque quantity and severity in postmenopausal women. Atherosclerosis 2001;157:471-9.
33. Makela R, Dastidar P, Jokela H, Saarela M, Punnonen R, Lehtimaki T. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism. J Clin Endocrinol Metab 2003;88:3823-8.
34. Furberg CD, Byington RP, Borhani NA. Multicenter isradipine diuretic atherosclerosis study (MIDAS). Design features. The Midas Research Group. Am J Med 1989;86:37-9.
35. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
36. Nquven T, Warnig R. Improved method for separation of total HDL cholesterol and subclasses. Clinical chemistry 1989;35:1086.
37. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
38. Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest 1987;47:739-44.
39. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res 2000;60:644-9.
40. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
41. Gabriel SR, Carmona L, Roque M, Sanchez GL, Bonfill X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005:CD002229.
42. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605-19.
43. Baker L, Meldrum KK, Wang M, Sankula R, Vanam R, Raiesdana A, et al. The role of estrogen in cardiovascular disease. J Surg Res 2003;115:325-44.
44. Stork S, Van Der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab 2004;15:66-72.
45. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997;3:324-7.
46. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 2004;109:234-41. Epub 2003 Dec 29.
47. Zhu X, Bonet B, Gillenwater H, Knopp RH. Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis. Proc Soc Exp Biol Med 1999;222:214-21.
48. Zhu XD, Bonet B, Knopp RH. 17Beta-estradiol, progesterone, and testosterone inversely modulate low-density lipoprotein oxidation and cytotoxicity in cultured placental trophoblast and macrophages. Am J Obstet Gynecol 1997;177:196-209.
49. Arteaga E, Rojas A, Villaseca P, Bianchi M, Arteaga A, Duran D. In vitro effect of estradiol, progesterone, testosterone, and of combined estradiol/progestins on low density lipoprotein (LDL) oxidation in postmenopausal women. Menopause 1998;5:16-23.
50. McManus J, McEneny J, Young IS, Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996;25:125-31.
51. McManus J, McEneny J, Thompson W, Young IS. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis 1997;135:73-81.
52. Sack MN, Rader DJ, Cannon RO, 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
53. Wakatsuki A, Ikenoue N, Sagara Y. Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women. Maturitas 1998;28:229-34.
54. Heikkinen AM, Niskanen L, Yla-Herttuala S, Luoma J, Tuppurainen MT, Komulainen M, et al. Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 1998;29:155-61.
55. Hermenegildo C, Garcia-Martinez MC, Tarin JJ, Llacer A, Cano A. The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size. Maturitas 2001;38:287-95.
56. Kabutomori O, Yanagihara T, Iwatani Y, Kawarazaki A, Kabutomori M. Sex difference in myeloperoxidase activity of neutrophils. Am J Hematol 1999;60:312-3.
57. Bekesi G, Magyar Z, Kakucs R, Sprintz D, Kocsis I, Szekacs B, et al. Changes in the myeloperoxidase activity of human neutrophilic granulocytes and the amount of enzyme deriving from them under the effect of estrogen. Orv Hetil 1999;140:1625-30.
58. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004;116:429-30.
59. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 2004;279:8300-15. Epub 2003 Dec 10.
60. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, et al. MPO and APOEepsilon4 polymorphisms interact to increase risk for AD in Finnish males. Neurology 2000;55:1284-90.